Coronavirus medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 19: | Line 19: | ||
::* [[Corticosteroids]] increases risk of fungal infections, some studies showed a higher incidence of psychosis, diabetes, avascular necrosis and osteoporosis | ::* [[Corticosteroids]] increases risk of fungal infections, some studies showed a higher incidence of psychosis, diabetes, avascular necrosis and osteoporosis | ||
::* Inhaled [[Nitric oxide]] potent mediator of airway inflammation, its has improved oxygenation in some studies | ::* Inhaled [[Nitric oxide]] potent mediator of airway inflammation, its has improved oxygenation in some studies | ||
=== Management of 2019-nCoV infection === | |||
* Given the emergence of the cases during the influenza season, all patients presenting with 2019-nCoV pneumonia were given oral and intravenous antibiotics and Oseltamivir (75 mg twice daily via oral route) empirically.<ref name="HuangWang2020">{{cite journal|last1=Huang|first1=Chaolin|last2=Wang|first2=Yeming|last3=Li|first3=Xingwang|last4=Ren|first4=Lili|last5=Zhao|first5=Jianping|last6=Hu|first6=Yi|last7=Zhang|first7=Li|last8=Fan|first8=Guohui|last9=Xu|first9=Jiuyang|last10=Gu|first10=Xiaoying|last11=Cheng|first11=Zhenshun|last12=Yu|first12=Ting|last13=Xia|first13=Jiaan|last14=Wei|first14=Yuan|last15=Wu|first15=Wenjuan|last16=Xie|first16=Xuelei|last17=Yin|first17=Wen|last18=Li|first18=Hui|last19=Liu|first19=Min|last20=Xiao|first20=Yan|last21=Gao|first21=Hong|last22=Guo|first22=Li|last23=Xie|first23=Jungang|last24=Wang|first24=Guangfa|last25=Jiang|first25=Rongmeng|last26=Gao|first26=Zhancheng|last27=Jin|first27=Qi|last28=Wang|first28=Jianwei|last29=Cao|first29=Bin|title=Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China|journal=The Lancet|year=2020|issn=01406736|doi=10.1016/S0140-6736(20)30183-5}}</ref> | |||
==References== | ==References== | ||
Revision as of 15:20, 5 February 2020
|
Coronavirus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Coronavirus medical therapy On the Web |
|
American Roentgen Ray Society Images of Coronavirus medical therapy |
|
Risk calculators and risk factors for Coronavirus medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
Treatment of coronavirus infection includes supportive measures and symptomatic management. No specific treatment is available.
Medical Therapy
Treatment should be supportive. No specific treatment available. Most people with coronavirus illness will recover on their own. However, some things can be done to relieve symptoms.
- Taking pain and fever medications (aspirin should not be given to children).
- Using a room humidifier or taking a hot shower to help ease a sore throat and cough.
- Drinking plenty of liquids, staying home and taking rest.
- Severe acute respiratory distress syndrome- coronavirus[1][2][3]
- Preferred regimen: supportive therapy
- Note: New therapies were studied for SARS during the last outbreaks which concluded:
- Ribavirin ineffective and probably harmful due to haemolytic anaemia
- Lopinavir PLUS Ritonavir is still controversial and need further investigation
- Interferon has no benefit and its studies are inconclusive
- Corticosteroids increases risk of fungal infections, some studies showed a higher incidence of psychosis, diabetes, avascular necrosis and osteoporosis
- Inhaled Nitric oxide potent mediator of airway inflammation, its has improved oxygenation in some studies
Management of 2019-nCoV infection
- Given the emergence of the cases during the influenza season, all patients presenting with 2019-nCoV pneumonia were given oral and intravenous antibiotics and Oseltamivir (75 mg twice daily via oral route) empirically.[4]
References
- ↑ Gilbert, David (2014). The Sanford guide to antimicrobial therapy 2014. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808782.
- ↑ Stockman LJ, Bellamy R, Garner P (2006). "SARS: systematic review of treatment effects". PLoS Med. 3 (9): e343. doi:10.1371/journal.pmed.0030343. PMC 1564166. PMID 16968120.
- ↑ Groneberg DA, Poutanen SM, Low DE, Lode H, Welte T, Zabel P (2005). "Treatment and vaccines for severe acute respiratory syndrome". Lancet Infect Dis. 5 (3): 147–55. doi:10.1016/S1473-3099(05)01307-1. PMID 15766649.
- ↑ Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin (2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". The Lancet. doi:10.1016/S0140-6736(20)30183-5. ISSN 0140-6736.